Christoph Neumann

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Ashkan Shoamanesh, Hardi Mundl, Eric E. Smith et al. · The Lancet · 2022 · 181 citations · Full text

Thrombosis, Cardiovascular Disease, Ischemic Stroke +14

Should Entrepreneurially Oriented Firms Have Narcissistic CEOs?

Andreas Engélen, Christoph Neumann, Susanne Schmidt · Journal of Management · 2013 · 177 citations

Entrepreneurial Phenomenon, Firm Performance, Management +14

Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial

Sonia S. Anand, John W. Eikelboom, Leanne Dyal et al. · Journal of the American College of Cardiology · 2019 · 121 citations · Full text

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Jonathan P. Piccini, Manesh R. Patel, Jan Steffel et al. · New England Journal of Medicine · 2024 · 117 citations · Full text